1747 BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER: OUTCOME RESULTS WITH 10 YEARS MINIMUM FOLLOW-UP

You have accessJournal of UrologyProstate Cancer: Localized VII1 Apr 20101747 BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER: OUTCOME RESULTS WITH 10 YEARS MINIMUM FOLLOW-UP Douglas Swartz, Mitchell Terk, Apoorva Vashi, Jamie Cesaretti, Rosetta Hickson, and Rizwan Nurani Douglas SwartzDouglas Swartz More articles by this author , Mitchell TerkMitchell Terk More articles by this author , Apoorva VashiApoorva Vashi More articles by this author , Jamie CesarettiJamie Cesaretti More articles by this author , Rosetta HicksonRosetta Hickson More articles by this author , and Rizwan NuraniRizwan Nurani More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1596AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To examine the biochemical control rate (bNED) in men treated with clinically localized prostate cancer (PCa) with a minimum of 10 years follow-up after prostate brachytherapy (BT). METHODS 2850 patients with clinically localized prostate cancer have undergone prostate BT at our institution since 1997. 158 patients were treated between July 1997 and August 1999. Only 18 of these patients have been lost to follow-up. This analysis reviews our initial 86 consecutive patients with low or intermediate risk disease, all with 10 years minimum follow-up. Risk stratification was assigned per the NCCN guidelines. All patients were followed prospectively in our IRB approved database and assessed for clinical and biochemical recurrence based on the Phoenix definition. Low-risk PCa patients were treated with Iodine-125 BT monotherapy. Intermediate risk PCa patients received combined modality therapy of a Pd-103 BT combined with low dose external beam radiation therapy (EBRT). 40 % of patients received short course hormonal therapy (HT) for a median of 6 months. RESULTS With a minimum of 10 years of follow-up, overall 93% of men were free from biochemical failure. On subset analysis per NCCN guidelines, 92% of patients who were low risk, and 96% of intermediate risk were free from biochemical failure at 10 years. No failures occurred after 5.5 years. 2% of patients developed grade 3 urinary toxicities and 2% developed grade 3 rectal toxicities. No grade 4 toxicities or secondary malignancies occurred. No patients developed rectal fistulae or ulceration. CONCLUSIONS Prostate seed implant in a high volume community center resulted in very low long-term biochemical failure rates in patients with low or intermediate risk disease. Long-term GU and GI toxicity were minimal. Our experience confirms the durability of biochemical control with no failures occurring beyond 5.5 years. This data represents one of the largest published series of non-actuarial 10-year outcomes. Jacksonville, FL© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e675 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Douglas Swartz More articles by this author Mitchell Terk More articles by this author Apoorva Vashi More articles by this author Jamie Cesaretti More articles by this author Rosetta Hickson More articles by this author Rizwan Nurani More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...